Agents for treating neurodegenerative disorders

Abstract

Compounds and methods of using these compounds to treat neurodegenerative diseases, especially Alzheimer's disease, are provided. The compounds that are provided for the treatment of neurodegenerative diseases can be represented by a general formula (I): wherein R1 is Me, Et or PhCH2; R2 is H, PhCH2 or 6-Me-3-Py-(CH2)2; and R3 is H, Me or Br. The solid line accompanied by the dotted line i.e. represents a single or double bond and salts thereof with pharmacologically acceptable acids and quaternary derivatives.

Description

BACKGROUND OF THE INVENTION [0001] 1. Field of the Invention [0002] The present invention relates to the use of chemical compounds in medicine, more specifically, to the use of the compounds selected from hydrogenated pyrido[4,3-b]indoles for the treatment of neurodegenerative diseases, and especially Alzheimer's disease (AD), due to the discovery of new properties intrinsic to these compounds. [0003] 2. Description of the Related Art [0004] Alzheimer's disease is currently one of the severest and widely spread neurodegenerative diseases. The most traditional approach to the treatment of this disease is compensatory therapy based on the compensation of the cholinergic system functions which are reduced in Alzheimer's disease. One of the therapeutic agents used in the alleged method of treatment is tacrine hydrochloride (hereinafter referred to as tacrine) which is 9-amino-1,2,3,4-tetrahydroacridine hydrochloride represented by the formula (A): [0005] The mechanism of action of the ...

AI Technical Summary

Benefits of technology

"The present invention provides compounds that can be used to treat neurodegenerative diseases, particularly Alzheimer's disease. These compounds are represented by a general formula (I) and can have different structures depending on the specific formula. The compounds can be in the form of a single or double bond, and can have salts with pharmacologically acceptable acids. The patent text describes specific examples of these compounds, such as 2-methyl-2,3,4,5-tetrahydro-1H-pyrido[4,3-b]indole and its dihydrochloride. The technical effect of this invention is the provision of new compounds that can be used to treat neurodegenerative diseases, particularly Alzheimer's disease."

Problems solved by technology

However, the treatment with tacrine is not always effective.

Besides, tacrine tends to cause undesirable side-effects.

As a result, the glutamate mediator at concentrations that are nontoxic under normal conditions becomes toxic for neurones under conditions of the developing β-amyloid dose and causes their death.

The main disadvantage of AP5 compound a side neurotoxic effect (such as the disturbance of coordination of movement and a sedative effect) which becomes apparent when AP5 is used in the doses in which it produces anti-NMDA effect (ED50=190 mg / kg) (Grigoriev et al., Chim. Pharm. Journal, 1988, No. 3, p.

However, to date such agents have not been available in clinics.

Images